Detalles de la búsqueda
1.
Safety and feasibility of establishing an adjuvant hepatic artery infusion program.
HPB (Oxford)
; 26(5): 656-663, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38383208
2.
Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC).
Br J Cancer
; 129(5): 782-790, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37443348
3.
Neoadjuvant therapy use and association with postoperative outcomes and overall survival in patients with extrahepatic cholangiocarcinoma.
J Surg Oncol
; 127(1): 90-98, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36194064
4.
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
Cancer
; 128(19): 3523-3530, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35895381
5.
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
Br J Cancer
; 127(6): 1153-1161, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35739299
6.
Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
Invest New Drugs
; 40(5): 1042-1050, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-35932388
7.
Short-Term Risk of Performing Concurrent Procedures with Hepatic Artery Infusion Pump Placement.
Ann Surg Oncol
; 27(13): 5098-5106, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32740732
8.
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.
Br J Clin Pharmacol
; 86(9): 1836-1848, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32207164
9.
Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Oncologist
; 24(8): 1039-e642, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31138725
10.
Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx®): a placebo-controlled randomised phase II study (PLIANT).
Acta Oncol
; 57(3): 393-402, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-29140155
11.
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
Nucleic Acids Res
; 44(9): 4105-22, 2016 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-26743006
12.
Risks and benefits of phase I liver dysfunction studies: should patients with severe liver dysfunction be included in these trials?
Invest New Drugs
; 35(3): 386-391, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28102465
13.
Advanced Cancer Patients' Understanding and Perceptions of Phase I Clinical Trials.
Cancer Invest
; 33(10): 490-5, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26460889
14.
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
BMC Cancer
; 15: 513, 2015 Jul 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26156229
15.
Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer.
Prostate
; 74(13): 1297-307, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25065737
16.
Kinetics in signal transduction pathways involving promiscuous oligomerizing receptors can be determined by receptor specificity: apoptosis induction by TRAIL.
Mol Cell Proteomics
; 11(3): M111.013730, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22213832
17.
Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.
Nucleic Acids Res
; 45(11): 6993, 2017 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28419278
18.
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Crit Rev Oncol Hematol
; 199: 104388, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754771
19.
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors.
Commun Med (Lond)
; 4(1): 10, 2024 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38218979
20.
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors.
Commun Med (Lond)
; 4(1): 95, 2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38773224